Rab Prinjha
Director/Board Member at Padlock Therapeutics, Inc.
Rab Prinjha active positions
| Companies | Position | Start | End |
|---|---|---|---|
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Director/Board Member | - | - |
Career history of Rab Prinjha
Former positions of Rab Prinjha
| Companies | Position | Start | End |
|---|---|---|---|
| GSK PLC | Corporate Officer/Principal | - | - |
Training of Rab Prinjha
| University College London | Doctorate Degree |
Statistics
International
| United Kingdom | 3 |
| United States | 2 |
Operational
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private companies | 1 |
|---|---|
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Rab Prinjha
- Experience
